---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-26T23:06:25.351402'
end_time: '2025-12-26T23:13:32.291326'
duration_seconds: 426.94
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: AP3B1
  gene_symbol: AP3B1
  uniprot_accession: O00203
  protein_description: 'RecName: Full=AP-3 complex subunit beta-1; AltName: Full=Adaptor
    protein complex AP-3 subunit beta-1; AltName: Full=Adaptor-related protein complex
    3 subunit beta-1; AltName: Full=Beta-3A-adaptin; AltName: Full=Clathrin assembly
    protein complex 3 beta-1 large chain;'
  gene_info: Name=AP3B1; Synonyms=ADTB3A;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the adaptor complexes large subunit family.
  protein_domains: AP3_beta. (IPR026740); AP3B1/2_C. (IPR056314); AP3B1_Ser. (IPR029394);
    AP3B_C. (IPR029390); AP_beta. (IPR026739)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 26
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O00203
- **Protein Description:** RecName: Full=AP-3 complex subunit beta-1; AltName: Full=Adaptor protein complex AP-3 subunit beta-1; AltName: Full=Adaptor-related protein complex 3 subunit beta-1; AltName: Full=Beta-3A-adaptin; AltName: Full=Clathrin assembly protein complex 3 beta-1 large chain;
- **Gene Information:** Name=AP3B1; Synonyms=ADTB3A;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the adaptor complexes large subunit family.
- **Key Domains:** AP3_beta. (IPR026740); AP3B1/2_C. (IPR056314); AP3B1_Ser. (IPR029394); AP3B_C. (IPR029390); AP_beta. (IPR026739)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AP3B1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AP3B1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AP3B1** (gene ID: AP3B1, UniProt: O00203) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O00203
- **Protein Description:** RecName: Full=AP-3 complex subunit beta-1; AltName: Full=Adaptor protein complex AP-3 subunit beta-1; AltName: Full=Adaptor-related protein complex 3 subunit beta-1; AltName: Full=Beta-3A-adaptin; AltName: Full=Clathrin assembly protein complex 3 beta-1 large chain;
- **Gene Information:** Name=AP3B1; Synonyms=ADTB3A;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the adaptor complexes large subunit family.
- **Key Domains:** AP3_beta. (IPR026740); AP3B1/2_C. (IPR056314); AP3B1_Ser. (IPR029394); AP3B_C. (IPR029390); AP_beta. (IPR026739)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AP3B1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AP3B1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AP3B1** (gene ID: AP3B1, UniProt: O00203) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity check: AP3B1 matches UniProt O00203, encoding the human AP-3 complex subunit beta-1 (β3A-adaptin) in Homo sapiens; literature confirms it as the large β subunit of the AP-3 adaptor complex and places it in the adaptor complexes large subunit family, aligning with the domain/family context provided (AP3_beta and related domains) (stockhammer2024localizationandfunction pages 21-24, newelllitwa2009rolesofbloc1 pages 1-2).

Key concepts and definitions (current understanding)
- AP3B1 and the AP-3 adaptor complex: Adaptor protein complex-3 (AP-3) is a heterotetramer (β, δ, μ, σ). AP3B1 encodes the β3A large subunit required for complex assembly and membrane recruitment, operating in post-Golgi/endosomal trafficking toward lysosomes and lysosome-related organelles (LROs) (Stockhammer 2024; Newell-Litwa 2009) (https://doi.org/10.1101/2023.10.27.564143; https://doi.org/10.1091/mbc.e08-05-0456) (stockhammer2024localizationandfunction pages 21-24, newelllitwa2009rolesofbloc1 pages 1-2).
- Isoforms and cell-type roles: Ubiquitous AP-3 (β3A/AP3B1) and neuronal AP-3 (β3B/AP3B2) have distinct roles; genetic analyses demonstrate differential effects on synaptic vesicle protein content versus lysosomal/endosomal routing, indicating isoform-specific cargo partitioning in neurons (Newell-Litwa 2009) (https://doi.org/10.1091/mbc.e08-05-0456) (newelllitwa2009rolesofbloc1 pages 1-2, newelllitwa2009rolesofbloc1 pages 9-10).
- Clathrin dependence: AP-3 can associate with clathrin but numerous studies observe AP-3 carriers lacking clathrin; yeast AP-3 trafficking is clathrin-independent, implicating alternative coats/tethers (e.g., HOPS/Vps41) (Stockhammer 2024) (https://doi.org/10.1101/2023.10.27.564143) (stockhammer2024localizationandfunction pages 21-24).

Subcellular localization and trafficking routes
- Sites of action: AP-3 localizes to the trans-Golgi network (TGN), tubular/peripheral endosomes, and generates carriers trafficking directly to late endosomes/lysosomes and LROs (e.g., melanosomes, platelet dense granules, lamellar bodies) (Newell-Litwa 2009; Stockhammer 2024) (https://doi.org/10.1091/mbc.e08-05-0456; https://doi.org/10.1101/2023.10.27.564143) (newelllitwa2009rolesofbloc1 pages 1-2, stockhammer2024localizationandfunction pages 21-24).
- Functional requirement demonstrated in vivo: In the pearl mouse (Ap3b1−/−), loss of β3A leads to dispersed AP-3 subunits and impaired membrane recruitment in platelets, melanocytes, and macrophages, with lysosomal morphological defects consistent with AP-3’s role in endosome/lysosome trafficking (Zhen 1999) (https://doi.org/10.1182/blood.v94.1.146.413k39_146_155) (zhen1999abnormalexpressionand pages 3-4).

Cargo recognition motifs and exemplar cargo
- Sorting motifs and cargo selection: AP-3 recognizes cytosolic sorting determinants including dileucine/acidic cluster motifs to package lysosomal and LRO cargo; established human cargo include LAMP1/LAMP2, CD63, tyrosinase, and endosomal/lysosomal enzymes and transporters (Stockhammer 2024) (https://doi.org/10.1101/2023.10.27.564143) (stockhammer2024localizationandfunction pages 21-24).
- Mechanistically validated cargo examples: Biochemical and genetic studies identify LAMP1, phosphatidylinositol-4-kinase type IIα (PI4KIIα), and the R-SNARE VAMP7 as AP-3 cargo; BLOC-1 loss phenocopies aspects of AP-3 deficiency for these cargos, indicating a cooperative sorting pathway (Salazar 2006) (https://doi.org/10.1091/mbc.e06-02-0103) (salazar2006bloc1complexdeficiency pages 10-11, salazar2006bloc1complexdeficiency pages 1-2).
- Additional pathway-relevant cargo: In neuronal/endosomal contexts, AP-3/BLOC-1 complexes associate with PI4KIIα; AP-3 influences synaptic vesicle and lysosomal protein distribution (Newell-Litwa 2009) (https://doi.org/10.1091/mbc.e08-05-0456) and broader endosomal network components such as ATP7A and VAMP7 are linked to AP-3/BLOC-1 pathways (Ryder 2013) (https://doi.org/10.1091/mbc.e13-02-0088) (newelllitwa2009rolesofbloc1 pages 9-10, hu2024pathogenesisandtherapy pages 2-3).

Mechanistic partners and regulators
- ARF1: AP-3, like other adaptor complexes, is recruited to membranes in an ARF1-regulated manner, although AP-3’s cargo-binding-competent conformation appears inherent; BLOC-1 deficiency does not impair ARF-GTP–dependent AP-3 recruitment, placing BLOC-1 downstream/parallel to coat recruitment (Stockhammer 2024; Salazar 2006) (https://doi.org/10.1101/2023.10.27.564143; https://doi.org/10.1091/mbc.e06-02-0103) (stockhammer2024localizationandfunction pages 21-24, salazar2006bloc1complexdeficiency pages 10-11).
- BLOC complexes and WASH: AP-3 functionally cooperates with BLOC-1 and BLOC-2 to assemble LROs; the WASH complex (endosomal Arp2/3 activator) interacts with BLOC-1 and its cargo PI4KIIα, integrating actin remodeling with AP-3/BLOC-mediated cargo sorting to lysosomes/LROs (Hu 2024; Ryder 2013; Salazar 2006) (https://doi.org/10.3390/ijms252011270; https://doi.org/10.1091/mbc.e13-02-0088; https://doi.org/10.1091/mbc.e06-02-0103) (hu2024pathogenesisandtherapy pages 2-3, salazar2006bloc1complexdeficiency pages 10-11, salazar2006bloc1complexdeficiency pages 1-2).

Disease relevance (Hermansky–Pudlak syndrome type 2; applications)
- Genetic cause and phenotypic core: Biallelic AP3B1 loss-of-function variants cause HPS-2, with a syndromic triad of oculocutaneous hypopigmentation, platelet dense-granule deficiency causing bleeding diathesis, and immunodeficiency (notably neutropenia) with recurrent infections; pulmonary fibrosis can occur in HPS and has been linked to AP-3 dysfunction as well as BLOC-3 defects (Neissi 2023; Hu 2024) (https://doi.org/10.1186/s43042-023-00421-1; https://doi.org/10.3390/ijms252011270) (neissi2023mutationalspectrumof pages 1-3, hu2024pathogenesisandtherapy pages 2-3).
- Expanded mutational spectrum (2023–2024 emphasis): A 2023 Iraqi family report described a novel homozygous nonsense AP3B1 variant c.892A>T (p.Arg298Ter) with albinism, prolonged bleeding, neutropenia, and severe infections; parental carriers were confirmed and the report summarized prior AP3B1 variants, providing a reference spectrum (Neissi 2023; accepted 23 Jun 2023) (https://doi.org/10.1186/s43042-023-00421-1) (neissi2023mutationalspectrumof pages 1-3, neissi2023mutationalspectrumof pages 5-5).
- Additional recent case data: A 2025 case from India expanded AP3B1 variants with a homozygous frameshift c.2212delA (p.Arg738Glufs*38) and classic HPS-2 features including neutropenia, recurrent infections, bleeding, and lung involvement; the paper reiterates a worldwide HPS prevalence estimate of roughly 1–9 per million (Gupta 2025; Jul 2025) (https://doi.org/10.1007/s44162-025-00084-z) (gupta2025hermanskypudlaksyndrome2 pages 5-7, gupta2025hermanskypudlaksyndrome2 pages 1-3).
- HLH risk and severe inflammatory complications: Collated references within the 2023 report note that HPS-2 has been associated with hemophagocytic lymphohistiocytosis in some patients, emphasizing the need for vigilant immune monitoring (Neissi 2023) (https://doi.org/10.1186/s43042-023-00421-1) (neissi2023mutationalspectrumof pages 5-5).

Diagnostics and real-world implementations
- Diagnostic workflow: For suspected HPS-2, recommended elements include: (a) genetic testing (NGS/WES) targeting HPS genes; (b) platelet electron microscopy to demonstrate absent/reduced dense granules; (c) platelet function testing (aggregometry; CD63 surface expression by flow cytometry) to corroborate storage pool defects; and (d) immunologic workup including neutrophil counts and infection history (Neissi 2023; Gupta 2025) (https://doi.org/10.1186/s43042-023-00421-1; https://doi.org/10.1007/s44162-025-00084-z) (neissi2023mutationalspectrumof pages 1-3, gupta2025hermanskypudlaksyndrome2 pages 5-7, gupta2025hermanskypudlaksyndrome2 pages 1-3).
- Management: Supportive bleeding control (e.g., antifibrinolytics, transfusion when necessary), infection prevention and prompt treatment given neutropenia/immunodeficiency, and pulmonary surveillance for fibrosis are central; genetic counseling is indicated for affected families (Gupta 2025; Hu 2024) (https://doi.org/10.1007/s44162-025-00084-z; https://doi.org/10.3390/ijms252011270) (gupta2025hermanskypudlaksyndrome2 pages 1-3, hu2024pathogenesisandtherapy pages 2-3).

Recent developments and latest research (prioritizing 2023–2024)
- Cell biology and mechanism (2024): Live-cell imaging and correlative microscopy refine the view that AP-3 occupies ARF1-positive tubulo-vesicular compartments at the Golgi/endosome interface; AP-3 shows context-dependent clathrin association and evidence for clathrin-independent budding routes (Stockhammer 2024 preprint; Oct 27, 2023 preprint DOI now published in 2024 venue) (https://doi.org/10.1101/2023.10.27.564143) (stockhammer2024localizationandfunction pages 21-24).
- HPS-associated pulmonary fibrosis (2024 review): Updated synthesis links AP-3 (HPS-2) and BLOC-3 dysfunction with LRO defects in alveolar type II cells and immune dysregulation contributing to progressive fibrosis; therapeutic landscape remains limited, underscoring need for targeted approaches (Hu 2024; Oct 2024) (https://doi.org/10.3390/ijms252011270) (hu2024pathogenesisandtherapy pages 2-3).
- Genetics/clinical (2023): New AP3B1 LoF variant (p.Arg298Ter) expands HPS-2 genotype-phenotype spectrum and provides recent clinical documentation of neutropenia and severe infections, reinforcing diagnostic algorithms that combine molecular and ultrastructural platelet analyses (Neissi 2023; Jun 2023) (https://doi.org/10.1186/s43042-023-00421-1) (neissi2023mutationalspectrumof pages 1-3).

Expert opinions and authoritative analyses
- Foundational mechanistic perspective: Newell-Litwa et al. argue that AP-3 and BLOC-1 form a functional module at early endosomes, orchestrating cargo sorting toward synaptic vesicles versus lysosomes/LROs, with isoform-specific effects in neurons (Mar 2009) (https://doi.org/10.1091/mbc.e08-05-0456) (newelllitwa2009rolesofbloc1 pages 1-2, newelllitwa2009rolesofbloc1 pages 9-10).
- Cooperative trafficking networks: Salazar et al. show that BLOC-1 deficiency alters targeting of AP-3 cargo (LAMP1, PI4KIIα, VAMP7), indicating tight cooperation between AP-3 and BLOC-1 in vesicle biogenesis for lysosomal/LRO routes (Sep 2006) (https://doi.org/10.1091/mbc.e06-02-0103) (salazar2006bloc1complexdeficiency pages 10-11, salazar2006bloc1complexdeficiency pages 1-2).
- In vivo relevance: Zhen et al. demonstrate that loss of β3A in the pearl mouse disrupts AP-3 membrane association and lysosomal homeostasis in hematopoietic and pigment cells, aligning with human HPS-2 organ system involvement (Jul 1999) (https://doi.org/10.1182/blood.v94.1.146.413k39_146_155) (zhen1999abnormalexpressionand pages 3-4).

Relevant statistics and data
- Prevalence: A representative HPS prevalence estimate of approximately 1–9 per 1,000,000 worldwide is cited in a recent case report (Gupta 2025; Jul 2025) (https://doi.org/10.1007/s44162-025-00084-z) (gupta2025hermanskypudlaksyndrome2 pages 1-3).
- Hematologic findings: Neutropenia with recurrent infections is characteristic in HPS-2; representative peripheral blood PMN counts in a 2023 report averaged 0.82 ± 0.45 G/L, with prolonged bleeding time despite normal PT/aPTT and platelet counts (Neissi 2023; Jun 2023) (https://doi.org/10.1186/s43042-023-00421-1) (neissi2023mutationalspectrumof pages 1-3).
- Platelet dense granules: Quantitative electron microscopy demonstrates reduced/absent dense granules in HPS-2; a 2025 case noted 3 ± 2.3 granules/platelet vs ~8 ± 2.4 in controls (Gupta 2025; Jul 2025) (https://doi.org/10.1007/s44162-025-00084-z) (gupta2025hermanskypudlaksyndrome2 pages 5-7).

Embedded summary artifact
| Aspect | Verified fact (evidence) |
|---|---|
| Identity verification | AP3B1 encodes the β3A large subunit of the heterotetrameric AP‑3 adaptor complex in Homo sapiens and contains AP3_beta family domains consistent with the UniProt entry (O00203) (stockhammer2024localizationandfunction pages 21-24, hu2024pathogenesisandtherapy pages 2-3). |
| AP‑3 composition & AP3B1 role | AP‑3 is a heterotetramer (β, δ, μ, σ); AP3B1 provides the β subunit required for complex assembly, membrane recruitment and functional coat activity (newelllitwa2009rolesofbloc1 pages 1-2, zhen1999abnormalexpressionand pages 3-4). |
| Subcellular localization & trafficking routes | AP‑3 localizes to the trans‑Golgi network and tubular/peripheral endosomes and mediates trafficking to lysosomes and lysosome‑related organelles (melanosomes, platelet dense granules, lamellar bodies); AP‑3 carriers show variable clathrin association and evidence for clathrin‑independent budding (newelllitwa2009rolesofbloc1 pages 1-2, stockhammer2024localizationandfunction pages 21-24, salazar2006bloc1complexdeficiency pages 10-11). |
| Cargo recognition & exemplar cargo | AP‑3 selects cargos via cytosolic sorting motifs (e.g., dileucine/acidic clusters) and sorts LAMP1/2, CD63, tyrosinase, ATP7A, PI4KIIα and SNARE VAMP7 among others, often requiring BLOC cofactors for effective recognition (salazar2006bloc1complexdeficiency pages 10-11, newelllitwa2009rolesofbloc1 pages 9-10, salazar2006bloc1complexdeficiency pages 1-2). |
| Mechanistic partners & regulators | AP‑3 function is coordinated with ARF1 (membrane recruitment), BLOC‑1/2 complexes and the WASH/actin machinery for endosomal sorting, and PI4KIIα acts both as an AP‑3 cargo and as a regulator of AP‑3 vesicles (stockhammer2024localizationandfunction pages 21-24, salazar2006bloc1complexdeficiency pages 10-11, salazar2006bloc1complexdeficiency pages 1-2, hu2024pathogenesisandtherapy pages 2-3). |
| Disease associations & hallmark phenotypes | Biallelic loss‑of‑function AP3B1 variants cause Hermansky‑Pudlak syndrome type 2 (HPS‑2): oculocutaneous hypopigmentation, platelet dense‑granule deficiency with bleeding, neutropenia with recurrent infections and elevated HLH risk, and predisposition to pulmonary fibrosis in some patients (neissi2023mutationalspectrumof pages 1-3, hu2024pathogenesisandtherapy pages 2-3, gupta2025hermanskypudlaksyndrome2 pages 5-7). |
| Diagnostics & real‑world applications | Clinical diagnosis relies on molecular testing (NGS/WES), platelet electron microscopy to show absent/reduced dense granules, aggregometry and flow cytometry, with management focused on supportive bleeding control, infection surveillance, lung monitoring and genetic counseling (neissi2023mutationalspectrumof pages 1-3, gupta2025hermanskypudlaksyndrome2 pages 5-7, gupta2025hermanskypudlaksyndrome2 pages 1-3, coronel2025síndromedehermanskypudlak pages 10-11). |
| Recent (2023–2024) updates | Recent reports expanded the AP3B1 mutational spectrum with novel homozygous/stop variants (Neissi et al., 2023) and reviews (2024) emphasize AP‑3/BLOC roles in HPS‑associated pulmonary fibrosis and updated cell‑biological analyses refine AP‑3 localization and clathrin‑independence discussions (neissi2023mutationalspectrumof pages 1-3, hu2024pathogenesisandtherapy pages 2-3, stockhammer2024localizationandfunction pages 21-24). |


*Table: Concise, evidence-backed summary of verified identity, molecular function, trafficking, cargos, partners, disease links and recent (2023–2024) clinical and mechanistic updates for human AP3B1 (UniProt O00203); each cell cites source IDs for reference.*

Conclusion
Human AP3B1 encodes the β3A subunit of AP-3, a heterotetrameric adaptor that localizes to TGN and endosomal subdomains to sort membrane proteins bearing canonical sorting signals into carriers bound for lysosomes and LROs. AP-3 works with ARF1, BLOC-1/2, and WASH-coordinated actin networks to route cargos including LAMP1/2, CD63, PI4KIIα, and VAMP7, with isoform-specific functions in neurons. Biallelic AP3B1 variants cause HPS-2, characterized by albinism, bleeding due to platelet dense-granule deficiency, neutropenia/immunodeficiency with infection risk (and HLH susceptibility), and potential pulmonary fibrosis. Recent (2023–2024) work refines AP-3’s clathrin independence and expands the AP3B1 variant spectrum, reinforcing the diagnostic pathway that integrates molecular testing with ultrastructural platelet analysis and guiding real-world management centered on bleeding control, infection vigilance, lung monitoring, and genetic counseling (stockhammer2024localizationandfunction pages 21-24, newelllitwa2009rolesofbloc1 pages 1-2, salazar2006bloc1complexdeficiency pages 10-11, salazar2006bloc1complexdeficiency pages 1-2, newelllitwa2009rolesofbloc1 pages 9-10, zhen1999abnormalexpressionand pages 3-4, hu2024pathogenesisandtherapy pages 2-3, neissi2023mutationalspectrumof pages 1-3, gupta2025hermanskypudlaksyndrome2 pages 5-7, gupta2025hermanskypudlaksyndrome2 pages 1-3, neissi2023mutationalspectrumof pages 5-5).

References

1. (stockhammer2024localizationandfunction pages 21-24): A Stockhammer. Localization and function of adaptor proteins in post-golgi transport. Unknown journal, 2024.

2. (newelllitwa2009rolesofbloc1 pages 1-2): Karen Newell-Litwa, Gloria Salazar, Yoland Smith, and Victor Faundez. Roles of bloc-1 and adaptor protein-3 complexes in cargo sorting to synaptic vesicles. Molecular biology of the cell, 20 5:1441-53, Mar 2009. URL: https://doi.org/10.1091/mbc.e08-05-0456, doi:10.1091/mbc.e08-05-0456. This article has 110 citations and is from a domain leading peer-reviewed journal.

3. (newelllitwa2009rolesofbloc1 pages 9-10): Karen Newell-Litwa, Gloria Salazar, Yoland Smith, and Victor Faundez. Roles of bloc-1 and adaptor protein-3 complexes in cargo sorting to synaptic vesicles. Molecular biology of the cell, 20 5:1441-53, Mar 2009. URL: https://doi.org/10.1091/mbc.e08-05-0456, doi:10.1091/mbc.e08-05-0456. This article has 110 citations and is from a domain leading peer-reviewed journal.

4. (zhen1999abnormalexpressionand pages 3-4): Lijie Zhen, Shelley Jiang, Lijun Feng, Nicholas A. Bright, Andrew A. Peden, Albert B. Seymour, Edward K. Novak, Rosemary Elliott, Michael B. Gorin, Margaret S. Robinson, and Richard T. Swank. Abnormal expression and subcellular distribution of subunit proteins of the ap-3 adaptor complex lead to platelet storage pool deficiency in the pearl mouse. Blood, 94 1:146-55, Jul 1999. URL: https://doi.org/10.1182/blood.v94.1.146.413k39\_146\_155, doi:10.1182/blood.v94.1.146.413k39\_146\_155. This article has 91 citations and is from a highest quality peer-reviewed journal.

5. (salazar2006bloc1complexdeficiency pages 10-11): G. Salazar, B. Craige, M. L. Styers, K. A. Newell-Litwa, M. M. Doucette, B. H. Wainer, J. M. Falcon-Perez, E. C. Dell’Angelica, A. A. Peden, E. Werner, and V. Faundez. Bloc-1 complex deficiency alters the targeting of adaptor protein complex-3 cargoes. Molecular biology of the cell, 17 9:4014-26, Sep 2006. URL: https://doi.org/10.1091/mbc.e06-02-0103, doi:10.1091/mbc.e06-02-0103. This article has 149 citations and is from a domain leading peer-reviewed journal.

6. (salazar2006bloc1complexdeficiency pages 1-2): G. Salazar, B. Craige, M. L. Styers, K. A. Newell-Litwa, M. M. Doucette, B. H. Wainer, J. M. Falcon-Perez, E. C. Dell’Angelica, A. A. Peden, E. Werner, and V. Faundez. Bloc-1 complex deficiency alters the targeting of adaptor protein complex-3 cargoes. Molecular biology of the cell, 17 9:4014-26, Sep 2006. URL: https://doi.org/10.1091/mbc.e06-02-0103, doi:10.1091/mbc.e06-02-0103. This article has 149 citations and is from a domain leading peer-reviewed journal.

7. (hu2024pathogenesisandtherapy pages 2-3): Xiao Hu, Zhixiao Wei, Yumeng Wu, Manhan Zhao, Liming Zhou, and Qiong Lin. Pathogenesis and therapy of hermansky–pudlak syndrome (hps)-associated pulmonary fibrosis. International Journal of Molecular Sciences, 25:11270, Oct 2024. URL: https://doi.org/10.3390/ijms252011270, doi:10.3390/ijms252011270. This article has 3 citations and is from a poor quality or predatory journal.

8. (neissi2023mutationalspectrumof pages 1-3): Mostafa Neissi and Adnan Issa Al-Badran. Mutational spectrum of the ap3b1 gene in an iraqi family affected with hermansky–pudlak syndrome type 2. Egyptian Journal of Medical Human Genetics, Jun 2023. URL: https://doi.org/10.1186/s43042-023-00421-1, doi:10.1186/s43042-023-00421-1. This article has 4 citations and is from a peer-reviewed journal.

9. (neissi2023mutationalspectrumof pages 5-5): Mostafa Neissi and Adnan Issa Al-Badran. Mutational spectrum of the ap3b1 gene in an iraqi family affected with hermansky–pudlak syndrome type 2. Egyptian Journal of Medical Human Genetics, Jun 2023. URL: https://doi.org/10.1186/s43042-023-00421-1, doi:10.1186/s43042-023-00421-1. This article has 4 citations and is from a peer-reviewed journal.

10. (gupta2025hermanskypudlaksyndrome2 pages 5-7): Vibha Gupta, R. Dave, Tulasi Geever, S. C. Nair, Joy Mammen, and N. A. Fouzia. Hermansky-pudlak syndrome 2 — a novel mutation with factor vii deficiency: a fluke from india. Journal of Rare Diseases, Jul 2025. URL: https://doi.org/10.1007/s44162-025-00084-z, doi:10.1007/s44162-025-00084-z. This article has 0 citations.

11. (gupta2025hermanskypudlaksyndrome2 pages 1-3): Vibha Gupta, R. Dave, Tulasi Geever, S. C. Nair, Joy Mammen, and N. A. Fouzia. Hermansky-pudlak syndrome 2 — a novel mutation with factor vii deficiency: a fluke from india. Journal of Rare Diseases, Jul 2025. URL: https://doi.org/10.1007/s44162-025-00084-z, doi:10.1007/s44162-025-00084-z. This article has 0 citations.

12. (coronel2025síndromedehermanskypudlak pages 10-11): Franklin Hidalgo Coronel, Julia Jaramillo Requena, Alejandra Cango Calderon, and Natalia Bailón Moscoso. Síndrome de hermansky-pudlak y sus mecanismos genéticos y fisiopatológicos. Indexia revista médico - científica, pages 32, Feb 2025. URL: https://doi.org/10.65183/revind.e13.06, doi:10.65183/revind.e13.06. This article has 0 citations.

## Citations

1. stockhammer2024localizationandfunction pages 21-24
2. zhen1999abnormalexpressionand pages 3-4
3. neissi2023mutationalspectrumof pages 5-5
4. hu2024pathogenesisandtherapy pages 2-3
5. neissi2023mutationalspectrumof pages 1-3
6. https://doi.org/10.1101/2023.10.27.564143;
7. https://doi.org/10.1091/mbc.e08-05-0456
8. https://doi.org/10.1101/2023.10.27.564143
9. https://doi.org/10.1091/mbc.e08-05-0456;
10. https://doi.org/10.1182/blood.v94.1.146.413k39_146_155
11. https://doi.org/10.1091/mbc.e06-02-0103
12. https://doi.org/10.1091/mbc.e13-02-0088
13. https://doi.org/10.3390/ijms252011270;
14. https://doi.org/10.1091/mbc.e13-02-0088;
15. https://doi.org/10.1186/s43042-023-00421-1;
16. https://doi.org/10.3390/ijms252011270
17. https://doi.org/10.1186/s43042-023-00421-1
18. https://doi.org/10.1007/s44162-025-00084-z
19. https://doi.org/10.1007/s44162-025-00084-z;
20. https://doi.org/10.1091/mbc.e08-05-0456,
21. https://doi.org/10.1182/blood.v94.1.146.413k39\_146\_155,
22. https://doi.org/10.1091/mbc.e06-02-0103,
23. https://doi.org/10.3390/ijms252011270,
24. https://doi.org/10.1186/s43042-023-00421-1,
25. https://doi.org/10.1007/s44162-025-00084-z,
26. https://doi.org/10.65183/revind.e13.06,